Quelling of Excitotoxicity in Acute Stroke With Ketamine
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The investigators plan to undertake a phase II study to investigate the efficacy and side
effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide
neuroprotection in patients diagnosed with acute ischemic stroke.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Doylestown Health Lower Merion Neurology Research Foundation